Trial Profile

Optimal dose of ACE inhibitor for treatment of diabetic nephropathy in type 1 diabetic patients with hypertension and diabetic nephropathy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lisinopril (Primary)
Indications Diabetic nephropathies; Hypertension; Proteinuria
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

01 Oct 2009 Results reported at 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
01 Sep 2009 Results published in Diabetes Care.
01 Jan 2009 Primary endpoint 'Albumin excretion rate' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com